119.48
-0.33
(-0.28%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 119.22 - 120.74 |
| 52 week | 98.25 - 121.33 |
| Open | 120.32 |
| Vol / Avg. | 493,749.00/477,348.00 |
| Mkt cap | 11.24B |
| P/E | 26.19 |
| Div/yield | 0.09/0.30 |
| EPS | 4.56 |
| Shares | 94.04M |
| Beta | 0.69 |
| Inst. own | 76% |
Events
Aug 12, 2013
Q4 2013 Perrigo Company Earnings Release
May 20, 2013
Perrigo Company at UBS Global Healthcare Conference
- 3:00PM EDT -
May 14, 2013
Perrigo Company at Bank of America Merrill Lynch Health Care Conference
May 7, 2013
Q3 2013 Perrigo Company Earnings Conference Call
May 7, 2013
Q3 2013 Perrigo Company Earnings Release
Mar 13, 2013
Perrigo Company at Barclays Healthcare Conference
Feb 27, 2013
Perrigo Company at RBC Capital Markets' Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 12.17% | 12.38% |
| Operating margin | 19.42% | 17.94% |
| EBITD margin | - | 22.48% |
| Return on average assets | 10.21% | 10.90% |
| Return on average equity | 20.73% | 23.25% |
| Employees | 8,800 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products and active pharmaceutical ingredients (API). The Company is the store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company has four segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals and API. In addition, the Company has an Other category that consists of the Israel Pharmaceutical and Diagnostic Products operating segment. In February 2013, it completed the acquisition of Leeds, United Kingdom-based Rosemont Pharmaceuticals Ltd. In April 2013, it closed the acquisition of Velcera, Inc.
Officers and directors
| Joseph C. Papa | Chairman of the Board, President, Chief Executive Officer | |
| Judy L. Brown | Chief Financial Officer, Executive Vice President | |
| Todd W. Kingma | Executive Vice President, General Counsel, Secretary | |
| Douglas Boothe | Executive Vice President, General Manager - Perrigo Pharmaceuticals | |
| Scott F. Jamison | Executive Vice President, General Manager - Nutritionals | |
| Sharon Kochan | Executive Vice President, General Manager - International | |
| Jeffrey R. Needham | Executive Vice President, General Manager - Consumer Healthcare | |
| John T. Hendrickson | Executive Vice President - Global Operations and Supply Chain | |
| Thomas M. Farrington | Senior Vice President, Chief Information Officer | |
| Jatin Shah Ph.D. | Senior Vice President, Chief Scientific Officer |